Flu Vaccine Leader Seqirus Invests In Self-Amplifying mRNA

Roberta Duncan To Head Up Progam

 
• By Andrew McConaghie

Seqirus is pursuing self-amplifying RNA, a promising but more technically complex approach which could help it compete in the next generation of flu and pandemic vaccines.

Flu Vaccine NHS
Seqirus has been boosted by better-than-expected flu vaccine sales, but must invest to keep ahead of new competitors

More from Business

More from Scrip